1. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023
- Author
-
Edward M, Schaeffer, Sandy, Srinivas, Nabil, Adra, Yi, An, Daniel, Barocas, Rhonda, Bitting, Alan, Bryce, Brian, Chapin, Heather H, Cheng, Anthony Victor, D'Amico, Neil, Desai, Tanya, Dorff, James A, Eastham, Thomas A, Farrington, Xin, Gao, Shilpa, Gupta, Thomas, Guzzo, Joseph E, Ippolito, Michael R, Kuettel, Joshua M, Lang, Tamara, Lotan, Rana R, McKay, Todd, Morgan, George, Netto, Julio M, Pow-Sang, Robert, Reiter, Mack, Roach, Tyler, Robin, Stan, Rosenfeld, Ahmad, Shabsigh, Daniel, Spratt, Benjamin A, Teply, Jonathan, Tward, Richard, Valicenti, Jessica Karen, Wong, Ryan A, Berardi, Dorothy A, Shead, and Deborah A, Freedman-Cass
- Subjects
Male ,Humans ,Prostatic Neoplasms ,Risk Assessment - Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
- Published
- 2022